Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia

Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for the treatment of patients with chronic myelogenous leukaemia (C…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news